Shares of Ocugen Inc. OCGN rallied 5.49% to $1.04 Tuesday, on what proved to be an all-around great trading session for the ...

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Shares of Ocugen Inc. OCGN slid 7.44% to $0.98 Monday, on what proved to be an all-around positive trading session for the ...

Ocugen, a company in the healthcare sector, has experienced a notable decline in its stock price over the past week, dropping by 8.62%. Despite this downturn, analysts like Robert ...

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients ...

After a tumultuous year of layoffs and strategic shifts, a Philadelphia biotech company has found a lifeline through a merger ...

Ocugen To Present at BIO International Convention 2025. MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in ...

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger agreement to combine the companies in an all-stock ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

OCU410ST employs an adeno-associated virus platform for retinal delivery of the RORA gene, targeting Stargardt disease ...

The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase ...